Showing results (21-30 of 39) with videos related to

Sort By:
Pageof 4
Journal of Immunological Sciences|March 30, 2023
Leflunomide Confers Rapid Recovery from COVID-19 and is Coupled with Temporal Immunologic ChangesAda Alice Dona, James F Sanchez, Joycelynne M Palmer, et al.
Journal of Cellular Physiology|January 10, 2019
The Bcl-2 inhibitor venetoclax inhibits Nrf2 antioxidant pathway activation induced by hypomethylating agents in AMLLe Xuan Truong Nguyen, Estelle Troadec, Arjun Kalvala, et al.
Oncoimmunology|October 6, 2018
Daratumumab induces CD38 internalization and impairs myeloma cell adhesionJayeeta Ghose, Domenico Viola, Cesar Terrazas, et al.
Breast Cancer Research and Treatment|March 2, 2011
Pilot neoadjuvant trial in HER2 positive breast cancer with combination of nab-paclitaxel and lapatinibVirginia G Kaklamani, Kalliopi Siziopikou, Denise Scholtens, et al.
The Lancet. Haematology|July 27, 2024
Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 studyAlex F Herrera, Jasmine Zain, Kerry J Savage, et al.
Hemasphere|May 2, 2025
Nivolumab plus ifosfamide, carboplatin, and etoposide are a highly effective first salvage regimen in high-risk relapsed/refractory Hodgkin lymphomaMatthew Mei, Joycelynne Palmer, Hun Ju Lee, et al.
Blood|January 6, 2018
Copper 64-labeled daratumumab as a PET/CT imaging tracer for multiple myelomaEnrico Caserta, Junie Chea, Megan Minnix, et al.
Blood|June 20, 2023
Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockadeMatthew Mei, Lu Chen, James Godfrey, et al.
JCI Insight|October 9, 2019
MiR-16 regulates crosstalk in NF-κB tolerogenic inflammatory signaling between myeloma cells and bone marrow macrophagesJihane Khalife, Jayeeta Ghose, Marianna Martella, et al.
Iscience|July 18, 2022
Vaccine-induced spike- and nucleocapsid-specific cellular responses maintain potent cross-reactivity to SARS-CoV-2 Delta and Omicron variantsFlavia Chiuppesi, John A Zaia, Katelyn Faircloth, et al.
Pageof 4